<DOC>
	<DOCNO>NCT02016209</DOCNO>
	<brief_summary>platinum-based albumin-bound paclitaxel regimen advance non-small cell lung cancer ( NSCLC ) especially lung squamous cell carcinoma well tumor response rate safety solvent-based paclitaxel.However , safety efficacy uncertain neoadjuvant therapy .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Nanoparticle Albumin-bound Paclitaxel Lung Cancer</brief_title>
	<detailed_description>The main purpose study observe safety efficacy platinum-based albumin-bound paclitaxel regimen treatment non-small cell lung cancer ( NSCLC ) stage Ⅱ B IIIA .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1.Histological cytological diagnosis NSCLC Stage Ⅱ B IIIA . 2.18 year old 3.Performance Status 0 2 ; 4.Appraisable disease ; 5.patients tolerant chemotherapy ; 6.Total bilirubin 1.5 x upper limit normal ( ULN ) ; 7.Creatinine clearance 60ml/min ( calculate accord Cockcroftgault formula ) . 1.Any systemic anticancer treatment NSCLC；2.Local radiotherapy NSCLC；3.In study within five year prior start treatment NSCLC patient cancers.4.Any instability systemic disease ; 5.Allergic paclitaxel Platinum ; 6.Pregnant lactate woman ; 7.Other researcher believe fit group</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>